RTHP-23. Cs131 IMPLANTS FOR SALVAGE THERAPY OF RECURRENT HIGH GRADE GLIOMAS (HGG)
CONCLUSION:We report the first experience using Cs131 brachytherapy in patients with recurrent HGG. Cs 131 implant may be considered a safe and effective treatment in this group of patients with limited salvage options. (Source: Neuro-Oncology)
Source: Neuro-Oncology - November 6, 2016 Category: Cancer & Oncology Authors: Youssef, E., Thomas, T., McBride, H., Nakaji, P., Smith, K., Brachman, D. Tags: RADIATION THERAPY Source Type: research
Rthp-22. inflammatory response after modified nanotherm and radiotherapy of recurrent glioblastoma
CONCLUSION:This is the first report demonstrating that the combination of modified NanoTherm therapy with radiotherapy can induce a strong inflammatory reaction at the resection cavity mimicking abscess formation. We assume that large amounts of cellular debris are released in situ, which can serve as a source of tumor antigens to elicit host CD8+T-cell mediated adaptive immune responses against the tumor. Further investigations are necessary to decipher immune-related effects of modified NanoTherm therapy. (Source: Neuro-Oncology)
Source: Neuro-Oncology - November 6, 2016 Category: Cancer & Oncology Authors: Grauer, O., Jaber, M., Hess, K., Weckesser, M., Schwindt, W., Maring, S., Stummer, W., Wölfer, J. Tags: RADIATION THERAPY Source Type: research
Rthp-21. clinical outcomes and pattern of failure in newly diagnosed glioblastoma multiforme treated with dose escalation intensity modulated radiotherapy (imrt)
CONCLUSION:Initial outcome of escalated radiation dose IMRT showed improvement of overall survival and progression free survival. The radiation dose escalation did not change pattern of recurrence, which was still locally in field failure. (Source: Neuro-Oncology)
Source: Neuro-Oncology - November 6, 2016 Category: Cancer & Oncology Authors: Ruetairuengnont, T., Chakkabat, C. Tags: RADIATION THERAPY Source Type: research
Rthp-20. evaluation of radiation therapy technology and dosimetry impact on treatment outcome for glioblastoma patients
CONCLUSION:Average brain and brainstem dose as well as BTV were strongly associated with OS, and might aid prognostication. VMAT and IGRT technology allowed for reduction of doses to healthy brain, including the hippocampi, which may reduce toxicity and preserve cognition. The benefit of VMAT and IGRT technology was not offset by a reduction of PFS or OS. (Source: Neuro-Oncology)
Source: Neuro-Oncology - November 6, 2016 Category: Cancer & Oncology Authors: Rosenschold, P. M. a., Law, I., Engelholm, S. A., Muhic, A., Lundemann, M., Roed, H., Grunnet, K., Poulsen, H. S. Tags: RADIATION THERAPY Source Type: research
Rthp-19. analysis of glioblastoma physical characteristics in patients benefiting from tumor treating electric fields therapy
Tumor treating electric fields (TTFields) are an established treatment for glioblastoma (GBM) patients. However, the anatomical and physical characteristics of the brain and tumor contributing to treatment efficacy are not well understood. We contoured gross tumor volume (GTV) using ScanIP and measured tumor size according to the RANO criteria on 5 patients with recurrent GBMs who exhibited a benefit from TTFields (cohort 1) and 5 who did not show any change (cohort 2). Tumor surface area and geometric centroid distance (GCD) from the bilateral ventricles were computed. Wilcoxon rank sum test was used to compare these...
Source: Neuro-Oncology - November 6, 2016 Category: Cancer & Oncology Authors: San, P. Tags: RADIATION THERAPY Source Type: research
Rthp-18. liquid biopsy distinguishes recurrent gbm from radiation necrosis in peripharal blood of patients with gbm
Glioblastoma (GBM) is the most aggressive and lethal type of brain cancer with a median survival of less than two years even with aggressive treatment. Among the many challenges in treating patients with this devastating disease is the ability to differentiate radiation induced change, often termed "radiation necrosis" from true GBM recurrence (rGBM). Radiation necrosis (RN) and GBM are very difficult to distinguish using standard Magnetic Resonance Imaging (MRI), and RANO criterion. Only a brain biopsy, an invasive procedure, can conclusively differentiate them. Recent studies by our group and others have demonstrated the...
Source: Neuro-Oncology - November 6, 2016 Category: Cancer & Oncology Authors: Soler, D., Young, A., Cooper, K., McCormick, T., Sloan, A. Tags: RADIATION THERAPY Source Type: research
Rthp-17. compliance of tumor treating electric fields therapy and overall survival in glioblastoma
Tumor treating electric fields (TTFields) at 200 kHz is an established therapeutic modality for glioblastoma. These fields exert anti-tumor effects by disrupting tumor cell cytokinesis during metaphase to anaphase transition. Since TTFields therapy has no half-life, uninterrupted application of TTFields at a daily compliance rate of 75% (18 out of 24 hours) is advocated to achieve optimal survival outcome. To confirm the benefit of this compliance rate, we used an unsupervised, binary partitioning algorithm to determine the daily compliance rate and the cumulative compliance that yielded the greatest statistical significan...
Source: Neuro-Oncology - November 6, 2016 Category: Cancer & Oncology Authors: Wong, E., Fong, J. Tags: RADIATION THERAPY Source Type: research
Rthp-16. multi-criteria optimization for srs of multiple lesions by single isocenter using taguchi approach coupled with principal component analysis
CONCLUSION:Results were analyzed using ANOVA and were found to be within the confidence interval. Further investigation using this methodology. Such parameters might include: virtual OAR and optimization criterion such as normal tissue objective. (Source: Neuro-Oncology)
Source: Neuro-Oncology - November 6, 2016 Category: Cancer & Oncology Authors: Alani, S., Honig, N. Tags: RADIATION THERAPY Source Type: research
Rthp-15. neural stem cell niche involvement and patterns of failure in glioblastoma multiforme
CONCLUSION:In our cohort, pre treatment NSC involvement was associated with a significantly higher incidence of distant brain failure and multifocal recurrences. Though it did not reach significance, baseline NSC involvement might be associated with inferior PFS and OS. Prospective validation in a larger cohort is necessary. (Source: Neuro-Oncology)
Source: Neuro-Oncology - November 6, 2016 Category: Cancer & Oncology Authors: Achari, R. B., Saha, A. Tags: RADIATION THERAPY Source Type: research
RTHP-14. TREATMENT RESULTS OF STEREOTACTIC RADIOTHERAPY AND BEVACIZUMAB (SRT-Bv) FOR RECURRENT GLIOBLASTOMA
CONCLUSION:SRT with bevacizumab is a safe and considerable treatment option for recurrent glioblastoma. (Source: Neuro-Oncology)
Source: Neuro-Oncology - November 6, 2016 Category: Cancer & Oncology Authors: Yasuda, T., Nitta, M., Maruyama, T., Tsuduki, S., Muragaki, Y., Kawamata, T. Tags: RADIATION THERAPY Source Type: research
Rthp-13. secondary malignancy rates and adverse radiation effects after stereotactic radiosurgery for benign acoustic neuroma: an institutional experience
CONCLUSION:Including L2-L3 patients, 2.2% of patients may develop a secondary neoplasm due to GKRS after 3-year follow-up. 2.9% may develop adverse effects. No secondary neoplasms found in our cohort were malignant, and most were slow-growing, benign neoplasms posing little neurologic threat. Our data suggest that patients may be re-assured that any post-treatment de novo neoplasms are likely to be benign. Our findings are consistent with estimated secondary malignancy rates of .01 to .1% at ten years. (Source: Neuro-Oncology)
Source: Neuro-Oncology - November 6, 2016 Category: Cancer & Oncology Authors: Saadatmand, H., Nanda, T., Nanda, P., Wu, C.-C., Lesser, J., Cheng, S., Afghan, M., Isaacson, S., Sheth, S., Wang, T., Sisti, M. Tags: RADIATION THERAPY Source Type: research
Rthp-12. non-operative management of acoustic neuroma in geriatric patients: a nationwide cancer database analysis
CONCLUSIONS:Fifteen percent of the AN population is at least age 65, with surgery by far the most commonly used treatment modality. Male gender and treatment at comprehensive cancer centers (by 40%) independently predicted receipt of radiation, while African-American race (by 50%) independently predicted receipt of observation. Given the proven impact of radiation therapy on local control in AN, and the relatively small proportion of geriatric patients receiving non-operative treatment, there is fertile ground for dissemination of radiation treatment for geriatric AN patients. (Source: Neuro-Oncology)
Source: Neuro-Oncology - November 6, 2016 Category: Cancer & Oncology Authors: McClelland, S., Murphy, J. D., Thomas, C. R. Tags: RADIATION THERAPY Source Type: research
Rthp-11. receipt of radiation treatment for acoustic neuroma: a national cancer database analysis of the impact of race and insurance status
CONCLUSIONS:Patients who were elderly, had a high-school degree, or were treated in comprehensive cancer centers were more likely to receive radiation for AN. Conversely, patients on Medicaid, having a Charlson/Deyo score of one, residing in the western United States, or with minimum household income of $48,000 were less likely to receive radiation for AN; receipt of radiation was not impacted by race. These findings indicate that patients with advanced age and/or treated at comprehensive cancer centers are being triaged to radiation for AN independent of race. Long-term nationwide outcome analyses will be needed to determ...
Source: Neuro-Oncology - November 6, 2016 Category: Cancer & Oncology Authors: McClelland, S., D Murphy, J., R Thomas, C. Tags: RADIATION THERAPY Source Type: research
Rthp-10. phase ii study of hypo vs. conventional -fractionated radiotherapy with temozolomide in newly diagnosed glioblastoma: early compliance and tolerance
CONCLUSION:Hypofractionated radiation appears to be well tolerated with no treatment interruption. However, longer follow up of the study will be able to conclude the possibility of incorporating hypo fractionation in regular treatment of newly diagnosed GBM. (Source: Neuro-Oncology)
Source: Neuro-Oncology - November 6, 2016 Category: Cancer & Oncology Authors: Mallick, S., parambath Haresh, K. Tags: RADIATION THERAPY Source Type: research
Rthp-09. progression and pseudoprogression of glioblastoma multiforme in the temozolomide era
CONCLUSIONS:Contrary to published reports, our data do not demonstrate an improvement in survival outcomes for patients with pseudoprogression compared to stable disease or response on first post-radiation imaging. Our data may be limited by patient numbers but importantly, there were no early imaging characteristics, including perfusion imaging, that differentiated pseudoprogression from true progression. These results underscore the need for continued investigations to develop non-invasive techniques to predict pseudoprogression and accurately predict overall survival. (Source: Neuro-Oncology)
Source: Neuro-Oncology - November 6, 2016 Category: Cancer & Oncology Authors: Rowe, L., Butman, J., Mackey, M., Shih, J., Hawes, M., Cooley Zgela, T., Ning, H., Smart, D., Gilbert, M., Camphausen, K., Krauze, A. Tags: RADIATION THERAPY Source Type: research
